-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 17, 2022, Frontiers in Oncology published a research result of academician Xu Binghe as the corresponding author, mainly to explore the clinicopathology of HER2-low expression (HER2-low) patients in HER2- breast cancer patients characteristics and clinical prognosis
On January 17, 2022, Frontiers in Oncology published a research result of academician Xu Binghe as the corresponding author, mainly to explore the clinicopathology of HER2-low expression (HER2-low) patients in HER2- breast cancer patients characteristics and clinical prognosis
The study screened 2202 patients between 2005 and 2015, and ultimately included 1433 patients, of whom 618 (43.
The study screened 2202 patients between 2005 and 2015, and ultimately included 1433 patients, of whom 618 (43.
Compared with HER2-0 patients, HER2-low patients had a higher proportion of HR positive (p<0.
Compared with HER2-0 patients, HER2-low patients had a higher proportion of HR positive (p<0.
The median follow-up time for the entire population was 62.
More specifically, in the overall patient population, HER2 IHC 2+ patients had better OS than HER2 IHC 1+ and HER2- 0 patients (88.
More specifically, in the overall patient population, HER2 IHC 2+ patients had better OS than HER2 IHC 1+ and HER2- 0 patients (88.
Subgroup analysis showed that patients with non-visceral metastases (HR: 0.
In HER2-negative patients, HER2-low tumors were independently associated with good OS (HR: 0.
In HER2-negative patients, HER2-low tumors were independently associated with good OS (HR: 0.
Taken together, these studies suggest that HER2-low tumors are a clinically distinct type, especially in the HR-positive subgroup, and may be an indicator of good prognosis in HER2- breast cancer patients
Taken together, these studies suggest that HER2-low tumors are a clinically distinct type, especially in the HR-positive subgroup, and may be an indicator of good prognosis in HER2- breast cancer patients
Original source:
Li Y, Abudureheiyimu N, Mo H, Guan X, Lin S, Wang Z, Chen Y, Chen S, Li Q, Cai R, Wang J, Luo Y, Fan Y, Yuan P, Zhang P, Li Q, Ma F and Xu B (2022) In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2- Negative Breast Cancer: A Study of the National Cancer Center, China.
Li Y, Abudureheiyimu N, Mo H, Guan X, Lin S, Wang Z, Chen Y, Chen S, Li Q, Cai R, Wang J, Luo Y, Fan Y, Yuan P, Zhang P, Li Q, Ma F and Xu B (2022) In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2- Negative Breast Cancer: A Study of the National Cancer Center, China.
Front.
Oncol.
11:774577.
doi: 10.
3389/ fonc.
2021.
774577
Leave a message here
